Summary
This Form 8-K filing from Alnylam Pharmaceuticals, Inc. announces the impending resignation of Dr. Victor J. Dzau from its Board of Directors, effective June 30, 2014. Dr. Dzau's departure is due to his upcoming appointment as President of the Institute of Medicine, a significant leadership role that necessitates his full attention. While this is a standard board transition, investors may note the departure of a director. Dr. Dzau will continue his service on the Board until his resignation date, ensuring a smooth handover. The filing does not disclose any immediate operational or financial changes, focusing solely on this board-level personnel update.
Key Highlights
- 1Dr. Victor J. Dzau, a member of Alnylam's Board of Directors, has confirmed his intention to resign.
- 2The resignation is effective June 30, 2014.
- 3The reason for resignation is Dr. Dzau's appointment as President of the Institute of Medicine, effective July 1, 2014.
- 4Dr. Dzau will continue to serve on the Board until his effective resignation date.
- 5This filing is made under Item 5.02 of Form 8-K, concerning departure of directors and officers.
- 6The filing date is February 26, 2014, with the earliest event reported on February 21, 2014.
Frequently Asked Questions
Dr. Victor J. Dzau is resigning from the Board of Directors.
Dr. Dzau's resignation will be effective on June 30, 2014.
Dr. Dzau is resigning because he has accepted the position of President of the Institute of Medicine, effective July 1, 2014, which will require his full commitment.
Yes, Dr. Dzau will continue to serve as a member of the Board until his effective resignation date of June 30, 2014.